Influence of treatment of Tourette Syndrome with Δ9-tetrahydrocannabinol (Δ9-THC) on neuropsychological performance

Pharmacopsychiatry

Volumn 34, Issue 1, 2001, Pages 19-24

  Muller Vahl K R ^a   Koblenz, A ^a   Jobges M ^a   Kolbe, H ^a   Emrich, H M ^a   Schneider, U ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS; DRONABINOL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; COMPULSION; FEMALE; GILLES DE LA TOURETTE SYNDROME; HUMAN; MALE; NEUROPSYCHOLOGICAL TEST; NEUROPSYCHOLOGY; OBSESSION; PHOBIA; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HALLUCINOGENS; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; TETRAHYDROCANNABINOL; TOURETTE SYNDROME;

EID: 0035144653     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-15191     Document Type: Article

References (66)

1. A visual retention test for clinical use
2. Acute effects of marijuana on cognition: Relationships to chronic effects and smoking techniques
3. Effects of chronic marijuana use on human cognition
4. A neurobiological model for Tourette syndrome centered on the nucleus accumbens
5. Presynaptic inhibition of GABAergic inputs to rat substantia nigra pars reticulata neurons by cannabinoid agonist
6. Tetrahydrocannabinol for tremor in multiple sclerosis
7. Comorbid behavioral disorders
8. The perceived effects of smoked cannabis on patients with multiple sclerosis
9. Open label evaluation of cannabidiol in dystonic movement disorders
10. Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents
11. SCL-90: An outpatient psychiatric rating scale - Preliminary report
12. Isolation and structure of a brain constituent that binds to the cannabinoid receptor
13. Towards a cannabinoid hypothesis of schizophrenia: Cognitive impairments due to dysregulation of the endogenous cannabinoid system
14. Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors
15. Psychologic and neuropsychologic aspects of Tourette Syndrome
16. Chronic (-)-delta9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats
17. Marihuana: Die rechtliche situation in Deutschland. Der stand der medizinischen Forschung
18. A rating scale for depression
19. Development of rating scale for primary depressive illness
20. Role of cannabinoid receptors in memory storage
21. VLMT. Verbaler Lern- und Merkfähigkeitstest
22. Effective treatment of Tourette Syndrome with marijuana
23. Cannabinoid receptor localization in brain
24. The two period cross-over clinical trial
25. Health aspects of cannabis
26. Delta 9-tetrahydrocannabinol increases prefrontal cortical catecholaminergic utilization and impairs spatial working memory in the rat: Blockade of dopaminergic effects with HA966
27. Event-related brain potentials show changed attentional mechanisms in Gilles de la Tourette syndrome
28. The Symptom Checklist-90: Obsessive-Compulsive Subscale: A reliability and validity study
29. Anandamide, an endogenous cannabinoid receptor ligand, also interacts with 5-hydroxytryptamine (5-HT) receptor
30. Psychische und soziale Konsequenzen des Cannabiskonsums
31. Future therapies
32. Clinical assessment of tic disorder severity
33. Localization of cannabinoid receptor in the human developing and adult basal ganglia. Higher levels in the striatonigral neurons
34. Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus
35. MWT-B - Ein Intelligenzkurztest
36. Ipsilateral turning behavior induced by unilateral microinjections of a cannabinoid into the rat subthalamic nucleus
37. Effects of a cannabinoid on spontaneous and evoked neuronal activity in the substantia nigra pars reticulata
38. Effect of maternal delta 9-tetrahydrocannabinol on developing serotonergic system
39. Cannabinoids: Possible role in pathophysiology of Gilles de la Tourette-syndrome
40. Treatment of Tourette-Syndrome with delta-9-Tetrahydrocannabinol
41. Hypothesis III. Tourette syndrome is only one of several causes of a developmental basal ganglia syndrome
42. The residual neuropsychological effects of cannabis: The current status of research
43. The residual cognitive effects of heavy marijuana use in college students
44. Marijuana and Tourette Syndrome
45. Cannabidiol in dystonic movement disorders
46. Role of the subthalamic nucleus in cannabinoid actions in the substantia nigra of the rat
47. Cannabinoid/anandamide system and schizophrenia: Is there evidence for association?
48. Short-term memory impairment in cannabis-dependent adolescents
49. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures
50. Delta9-tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture
51. The effects of the cannabinoid receptor agonist nabilone on L-DOPA induced dyskinesia in patients with idiopathic Parkinson's disease (PD)
52. Differential impairments of selective attention due to frequency and duration of cannabis use
53. Signal detection and identification at successive stages of observation
54. Cannabis and cognitive functions: A prospective study
55. A standardized memory scale for clinical use
56. Tourette Syndrome: A disorder of cingulate and orbitofrontal function?
57. The usefulness of the obsessive compulsive scale of the symptom checklist-90-revised
58. Frontocortical activity in children with comorbidity of tic disorder and attention-deficit hyperactivity disorder
59. Decreased motor inhibition in Tourette's disorder: Evidence from transcranial magnetic stimulation